(S1 (S (NP (CD Two) (JJ major) (NN drug) (NNS companies)) (VP (VBD posted) (NP (JJ strong) (JJ third-quarter) (NNS earnings)) (, ,) (PP (IN in) (NP (NP (NN line)) (PP (IN with) (NP (NP (NNS profits)) (VP (ADVP (RB already)) (VBN reported) (PP (IN by) (NP (NP (NN industry) (NNS leaders)) (CC and) (NP (NP (NNS analysts) (POS ')) (NNS expectations)))))))))) (. .)))

(S1 (S (CC But) (NP (NP (NNP Pfizer) (NNP Inc.)) (, ,) (VP (VBN based) (PP (IN in) (NP (NNP New) (NNP York)))) (, ,)) (VP (VBD reported) (NP (JJ flat) (NNS earnings))) (. .)))

(S1 (S (NP (NP (NNP Schering-Plough) (NNP Corp.)) (, ,) (VP (VBN based) (PP (IN in) (NP (NP (NNP Madison)) (, ,) (NP (NNP N.J.))))) (, ,)) (VP (VBD reported) (NP (NP (DT a) (ADJP (CD 21) (NN %)) (NN rise)) (PP (IN in) (NP (NNS earnings) (SBAR (IN as) (S (NP (NP (NNP American) (NNP Home) (NNPS Products) (NNP Corp.)) (PP (IN of) (NP (NNP New) (NNP York)))) (VP (VBD posted) (NP (NP (DT an) (ADJP (CD 11) (NN %)) (NN increase)) (PP (IN in) (NP (JJ net))))))))))) (. .)))

(S1 (NP (NNP American) (NNP Home) (NNP Products)))

(S1 (S (NP (NNP American) (NNP Home) (NNP Products)) (VP (VBD said) (SBAR (S (NP (NP (NNS sales) (CC and) (NNS earnings)) (PP (IN for) (NP (NP (DT the) (JJ third) (NN quarter)) (CC and) (NP (CD nine) (NNS months))))) (VP (VBD were) (PP (IN at) (NP (NN record) (NNS levels))))))) (. .)))

(S1 (S (NP (NP (NNS Sales)) (PP (IN for) (NP (DT the) (JJ third) (NN quarter)))) (VP (VBD increased) (NP (CD 6.5) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 1.51) (CD billion)))) (PP (IN from) (NP (QP ($ $) (CD 1.42) (CD billion))))) (. .)))

(S1 (S (NP (NP (NNS Sales)) (PP (IN of) (NP (NN health-care) (NNS products)))) (VP (VBD increased) (NP (CD 6) (NN %)) (PP (IN in) (NP (DT the) (JJ third) (NN quarter))) (, ,) (VP (VBN based) (PP (IN in) (NP (NP (NN part)) (PP (IN on) (NP (NP (JJ strong) (NNS sales)) (PP (IN of) (NP (NP (NN prescription) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NNP Premarin)) (, ,) (NP (DT an) (JJ estrogen-replacement) (NN drug)) (, ,)) (CC and) (NP (NP (NNS sales)) (PP (IN of) (NP (NP (DT the) (NN company) (POS 's)) (JJ infant) (NN formula)))))))))))))) (. .)))

(S1 (S (NP (NNP American) (NNP Home) (NNP Products)) (VP (VBD said) (SBAR (S (NP (JJ net) (NN income)) (VP (VBD benefited) (PP (IN from) (NP (NP (DT a) (`` `) (NP (`` `) (NP (JJR lower) (JJ effective) (NN tax) (NN rate)) (, ,) ('' ')) ('' ') (VP (VBG reflecting) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (JJ foreign) (NN tax) (NNS rates)))))) (, ,) (CC and) (NP (NP (JJ additional) (NNS operations)) (PP (IN in) (NP (NNP Puerto) (NNP Rico)))))))))) (. .)))

(S1 (S (NP (NN Net)) (ADVP (RB also)) (VP (VBD was) (VP (VBN aided) (PP (IN by) (NP (NP (DT a) (NN gain)) (PP (IN on) (NP (NP (DT the) (NN sale)) (PP (IN of) (NP (NP (NP (DT the) (NN company) (POS 's)) (NN equity) (NNS interests)) (PP (IN in) (NP (NNP South) (NNP Africa))) (ADJP (JJ effective) (NP (NNP Sept.) (CD 1))))))))))) (. .)))

(S1 (S (PP (IN In) (NP (NNP New) (NNP York) (NNP Stock) (NNP Exchange) (JJ composite) (NN trading))) (NP (NN yesterday)) (, ,) (NP (NNP American) (NNP Home) (NNP Products)) (VP (VBD closed) (PP (IN at) (NP (NP ($ $) (CD 102.25)) (NP (DT a) (NN share)))) (, ,) (ADVP (RB down) (NP (CD 75) (NNS cents)))) (. .)))

(S1 (NP (NNP Pfizer)))

(S1 (S (NP (NNP Pfizer)) (VP (VBD said) (SBAR (S (NP (JJ third-quarter) (NNS sales)) (VP (VBD increased) (NP (CD 4) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 1.44) (CD billion)))) (PP (IN from) (NP (QP ($ $) (CD 1.38) (CD billion)))))))) (. .)))

(S1 (S (NP (DT The) (NN company)) (VP (VBD said) (SBAR (S (NP (JJ net) (NN income)) (VP (VBD was) (ADJP (JJ flat)) (PP (IN because) (IN of) (NP (NP (NN investment)) (PP (IN in) (NP (NP (NN research) (CC and) (NN development)) (CC and) (NP (NP (NNS costs)) (VP (VBN related) (PP (TO to) (NP (NP (NNS launches)) (PP (IN of) (NP (JJ several) (NNS products))))))))))))))) (. .)))

(S1 (S (NP (DT The) (NN company)) (VP (VBD said) (SBAR (S (NP (NP (DT the) (NN dollar) (POS 's)) (JJ continued) (NN strengthening)) (VP (VBD reduced) (NP (JJ world-wide) (NNS sales) (NN growth)) (PP (IN by) (NP (CD three) (NN percentage) (NNS points))))))) (. .)))

(S1 (S (NP (NNP Pfizer)) (VP (VBD posted) (NP (NP (NP (PRP$ its) (JJS largest) (NNS gains)) (PP (IN in) (NP (NP (NNP healthcare) (NNS sales)) (, ,) (ADVP (RB up) (NP (CD 3) (NN %)))))) (, ,) (CC and) (NP (NN consumer) (NNS products))) (, ,) (ADVP (RB up) (NP (CD 23) (NN %)))) (. .)))

(S1 (S (S (NP (NP (NNS Sales)) (PP (IN by) (NP (DT the) (NN specialty) (NNS chemicals) (CC and) (NNS materials) (NN science) (NNS segments)))) (VP (VBD were) (ADJP (JJ flat)))) (, ,) (CC and) (S (NP (NP (NNS sales)) (PP (IN by) (NP (DT the) (NN agriculture) (NN segment)))) (VP (VBD declined) (NP (CD 5) (NN %)))) (. .)))

(S1 (S (PP (IN In) (NP (DT the) (NN health-care) (NN segment))) (, ,) (S (NP (JJ pharmaceutical) (NNS sales)) (VP (VBD increased) (NP (CD 4) (NN %)))) (CC and) (S (NP (NP (NNS sales)) (PP (IN of) (NP (NN hospital) (NNS products)))) (VP (VBD increased) (NP (CD 1) (NN %)))) (. .)))

(S1 (S (PP (IN During) (NP (DT the) (NN quarter))) (, ,) (NP (NNP Pfizer)) (VP (VBD received) (NP (NP (JJ federal) (NN approval)) (PP (IN of) (NP (NP (NP (NNP Procardia) (CD XL)) (, ,) (NP (NP (NP (DT a) (NN calcium) (NN channel) (NN blocker)) (VP (VBN approved) (PP (IN for) (NP (DT both) (NNS angina))))) (CC and) (NP (NN hypertension))) (, ,)) (CC and) (NP (NP (NNP Monorail) (NNP Piccolino)) (, ,) (VP (VBN used) (S (VP (TO to) (VP (VB open) (VP (VBN obstructed) (NP (JJ coronary) (NNS arteries)))))))))))) (. .)))

(S1 (S (PP (IN In) (NP (NNP New) (NNP York) (NNP Stock) (NNP Exchange) (JJ composite) (NN trading))) (NP (NN yesterday)) (, ,) (NP (NNP Pfizer)) (VP (VBD closed) (PP (IN at) (NP (NP ($ $) (CD 67.75)) (NP (DT a) (NN share)))) (, ,) (ADVP (RB up) (NP (CD 75) (NNS cents)))) (. .)))

(S1 (NP (NNP Schering-Plough)))

(S1 (S (NP (NNP Schering-Plough)) (VP (VBD said) (SBAR (S (NP (NNS sales)) (VP (VBD gained) (NP (CD 2.7) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 743.7) (CD million)))) (PP (IN from) (NP (QP ($ $) (CD 724.4) (CD million)))))))) (. .)))

(S1 (S (PP (IN In) (NP (DT the) (NN period))) (, ,) (NP (DT the) (NN company)) (VP (VP (VBD completed) (NP (NP (DT the) (NN sale)) (PP (IN of) (NP (PRP$ its) (NNP European) (NNS cosmetics) (NNS businesses))))) (, ,) (VP (VBD sold) (NP (NP (DT a) (NN majority) (NN interest)) (PP (IN in) (NP (PRP$ its) (JJ Brazilian) (NN affiliate))))) (, ,) (CC and) (VP (VBD announced) (NP (NP (DT the) (NN reorganization)) (PP (IN of) (NP (PRP$ its) (JJ over-the-counter) (NN drug) (NNS businesses))) (PP (IN into) (NP (NP (DT a) (JJ new) (NN unit)) (, ,) (NP (NNP Schering-Plough) (NNP Health) (NNP Care) (NNPS Products))))))) (. .)))

(S1 (S (NP (DT These) (NNS actions)) (VP (VBD did) (RB n't) (VP (VB affect) (NP (NNS results)) (SBAR (IN because) (S (NP (NP (DT the) (NN gain)) (PP (IN on) (NP (NP (DT the) (NN sale)) (PP (IN of) (NP (DT the) (NNP European) (NNS cosmetics) (NNS businesses)))))) (VP (VBD was) (VP (VBN offset) (PP (IN by) (NP (NP (NNS provisions)) (VP (VBG relating) (PP (TO to) (NP (DT the) (NX (NX (NNP Brazil) (NN divestiture)) (CC and) (NX (NN drug) (NN restructuring)))))))))))))) (. .)))

(S1 (S (NP (NNP U.S.) (JJ pharmaceutical) (NNS sales)) (VP (VBD rose) (NP (CD 15) (NN %)) (, ,) (S (VP (VBN led) (PP (IN by) (NP (NP (NN allergy)) (, ,) (NP (NP (UCP (NN asthma) (CC and) (JJ cold)) (NNS products)) (: ;) (NP (JJ dermatological) (NNS products)) (: ;) (NP (NP (NNS anti-infectives)) (CC and) (NP (JJ anti-cancer) (NNS products))) (: ;) (CC and) (NP (JJ cardiovascular) (NNS products)))))))) (. .)))

(S1 (S (NP (JJ World-wide) (NN consumer) (NN product) (NNS sales)) (VP (VBD declined) (NP (CD 12) (NN %)) (, ,) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (DT the) (NNP European) (NNS cosmetics) (NN sale)))) (. .)))

(S1 (S (NP (NP (ADJP (RB Significantly) (JJR lower)) (NNS sales)) (PP (IN of) (NP (`` `) (S (VP (VB Stay) (ADJP (JJ Trim)))) ('' ') (NN diet) (NNS aids)))) (ADVP (RB also)) (VP (VBD were) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (DT the) (NN drop))))) (. .)))

(S1 (S (NP (DT The) (NNP Maybelline) (NN beauty) (NN product) (NN line)) (VP (VBD had) (NP (JJR higher) (NNS sales)) (PP (VBG following) (NP (DT a) (JJ sluggish) (JJ first) (NN half)))) (. .)))

(S1 (S (PP (IN In) (NP (NNP Big) (NNP Board) (JJ composite) (NN trading))) (, ,) (NP (NNP Schering-Plough) (NNS shares)) (VP (VBD fell) (NP (CD 75) (NNS cents)) (S (VP (TO to) (VP (VB close) (PP (IN at) (NP ($ $) (CD 74.125))))))) (. .)))

